Exelixis (EXEL) Share-based Compensation (2010 - 2026)
Exelixis (EXEL) posted quarterly Share-based Compensation of $34.2 million for Q2 2026, up 52.03% year-over-year from $22.5 million in Q2 2025, and up 70.33% quarter-over-quarter from $20.1 million in Q1 2026.
Analysis
Exelixis (EXEL) Share-based Compensation (2010 - 2026) Analysis & Trends
Exelixis' Share-based Compensation history runs 17 years deep, the most recent figure standing at $34.2 million for Q2 2026.
- In Q2 2026, Share-based Compensation rose 52.03% year-over-year to $34.2 million; the TTM figure through Apr 2026 stood at $124.7 million (up 566.26% YoY), while the FY2026 annual figure was $113.0 million, up 637.82% from the prior year.
- Share-based Compensation for Q2 2026 stood at $34.2 million, up from $20.1 million in the prior quarter.
- The five-year high for Share-based Compensation was $91.5 million in Q4 2022, with the low at -$52.2 million in Q1 2025.
- The 5-year median for Share-based Compensation is $19.1 million (2024), against an average of $16.9 million.
- The sharpest annual moves came in 2022 and 2025: Share-based Compensation tumbled 1468.43% in 2022, then jumped 4282.35% in 2025.
- Exelixis' Share-based Compensation stood at $91.5 million in 2022, then slumped by 107.12% to -$6.5 million in 2023, then soared by 828.94% to $47.5 million in 2024, then plunged by 34.95% to $30.9 million in 2025, then advanced by 10.83% to $34.2 million in 2026.
- Business Quant data shows EXEL's Share-based Compensation at $34.2 million in Q2 2026, $20.1 million in Q1 2026, and $30.9 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 120.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 277.20 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 137.41 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 86.63 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Exelixis | 14.81 Bn | 13.97 Bn | 608.03 Mn | 36.34 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 3, 2026 | 36.34 Mn |
| Apr 3, 2026 | 34.23 Mn |
| Jan 2, 2026 | 20.10 Mn |
| Oct 3, 2025 | 29.87 Mn |
| Jul 4, 2025 | 37.09 Mn |
| Apr 4, 2025 | 25.93 Mn |
| Jan 3, 2025 | 26.35 Mn |
| Sep 27, 2024 | 23.02 Mn |
| Jun 28, 2024 | 25.35 Mn |
| Mar 29, 2024 | 19.11 Mn |
| Dec 29, 2023 | 24.31 Mn |
| Sep 29, 2023 | 40.48 Mn |
| Jun 30, 2023 | 24.90 Mn |
| Mar 31, 2023 | 16.66 Mn |
| Dec 30, 2022 | 33.98 Mn |
| Sep 30, 2022 | 1.60 Mn |
| Jul 1, 2022 | 100.60 Mn |
| Apr 1, 2022 | 19.76 Mn |
| Dec 31, 2021 | 23.17 Mn |
| Oct 1, 2021 | 33.97 Mn |